Known targets — ChEMBL curated mechanism
HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7SIGMAR1
The experimentally established mechanism targets of Levofenfluramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 1.00 |
| ▸ | HTR2B known ✓ | P41595 | 4/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.64 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.57 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.43 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.43 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.43 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexfenfluramine SCHEMBL16706 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL16215 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Dexfenfluramine SCHEMBL15669714 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL29447403 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Dexfenfluramine SCHEMBL29499611 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Levofenfluramine SCHEMBL29882976 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL23724055 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL11140094 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL39491 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Levofenfluramine SCHEMBL30951308 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3758 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2024130195-A1 | MACHINE LEARNING SYSTEMS AND METHODS FOR VALIDATING WORKFLOWS | INSURANCE SERVICES OFFICE, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| US-20240202631-A1 | Machine Learning Systems and Methods for Validating Workflows | INSURANCE SERVICES OFFICE, INC. (US) | 2024-06-20 | — | — | US | claimed |
| CN-112486489-B | Rendering method and device of auction component | 上海万物新生环保科技集团有限公司 | 2024-06-07 | — | — | CN | claimed |
| WO-2024064357-A1 | COMPOSITIONS AND METHODS TARGETING SWIP-10 AND MBLAC1 FOR THE THERAPEUTIC MODULATION OF COPPER DYSHOMEOSTASIS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2024-03-28 | — | — | WO | claimed |
| US-20240075043-A1 | IMMEDIATE AND CONTROLLED RELEASE APPETITE SUPPRESSANT COMPOSITIONS FOR WEIGHT LOSS | Red Mountain Med Spa, LLC (US) | 2024-03-07 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| CN-113031926-B | Transaction commission account book and span diagram display system and method | 库珀科技集团有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-117298570-A | Actor management method and device based on reduce and electronic equipment | 不鸣科技(杭州)有限公司 | 2023-12-29 | — | — | CN | claimed |
| US-5795880-A | Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent | LOUISIANA STATE UNIVERSITY MEDICAL CENTER FOUNDATION (US) | 1998-08-18 | — | — | US | claimed |
| WO-1998016211-A1 | METHOD FOR THE ENHANCEMENT OF LYMPHOCYTE ACTIVITY AGAINST OPPORTUNISTIC MICROBIAL PATHOGENS AND TUMORS | LOYOLA UNIVERSITY OF CHICAGO (US) | 1998-04-23 | — | — | WO | claimed |
| EP-0253146-B1 | THE USE OF D-FENFLURAMINE FOR THE MANUFACTURE OF MEDICAMENTS FOR TREATING DEPRESSION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1992-08-12 | — | — | EP | claimed |
| US-4857553-A | SIDE EFFECT REDUCTION | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-08-15 | — | — | US | claimed |
| US-4843019-A | MONOCLONAL ANTIBODIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1989-06-27 | — | — | US | claimed |
| EP-0302757-A2 | Anti-emetic serotonin depleting agents | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-02-08 | — | — | EP | claimed |
| EP-0253146-A2 | The use of D-Fenfluramine for the manufacture of medicaments for treating depression | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1988-01-20 | — | — | EP | claimed |
| EP-0197974-A1 | ACINO-FOETAL DIFFERENTIATION PROTEINS ASSOCIATED TO THE PANCREAS CANCER, ANTISERUM AND MONOCLONAL ANTIBODIES TO SAID PROTEINS, PREPARATION METHODS | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1986-10-22 | — | — | EP | claimed |
| EP-0180496-A1 | Acino-foetal differentiation proteins associated with cancer of the pancreas, antiserum and monoclonal antibodies against these proteins and processes for their preparation | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1986-05-07 | — | — | EP | claimed |
| WO-1986002081-A1 | ACINO-FOETAL DIFFERENTIATION PROTEINS ASSOCIATED TO THE PANCREAS CANCER, ANTISERUM AND MONOCLONAL ANTIBODIES TO SAID PROTEINS, PREPARATION METHODS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 1986-04-10 | — | — | WO | claimed |